For patients with localized prostate cancer (PCa), tissue-based genomic classifiers (GCs) do not consistently influence risk ...

Despite these advances, however, the disease remains fatal and is the second leading cause of cancer specific death in men over the age of 50 years old in the United States. This presentation will ...

The selective advantage for the establishment and, more interestingly, the maintenance of heterogeneity in tumors is unclear. Our results indicate that tumors benefit collectively from protecting ...

and this huge heterogeneity exists within the spectrum of prostate cancers as well. We've made huge progress in understanding prostate cancer's typical progression in people. We've grown quite ...